Last updated: April 25, 2026
Who Supplies RYALTRIS (olopatadine hydrochloride + fluticasone propionate) and What Can Be Attributed?
RYALTRIS is a branded, fixed-dose combination nasal spray containing olopatadine hydrochloride (antihistamine) and fluticasone propionate (corticosteroid). Public, citable disclosure of a complete, named supplier map (API sites, formulation sites, fill-finish contractors) is not present in the available materials set provided in this conversation.
No further supplier attribution can be produced without risking incorrect identification of manufacturers, contract development and manufacturing organizations, or packaging/fill-finish partners.
What Supplier Information Is Directly Attributable From This Context?
- No named suppliers (API, drug product, fill-finish, or packaging) are provided in the information available here.
- No contract manufacturer names or site addresses are available to map upstream supply.
What Is the Product Structure That Drives Supply Mapping?
| RYALTRIS component |
Role |
Typical supply chain step that has a supplier |
| Olopatadine hydrochloride |
API (antihistamine) |
API manufacturer(s) and solid-form control supplier(s) |
| Fluticasone propionate |
API (corticosteroid) |
API manufacturer(s) and particle/assay control supplier(s) |
| Fixed-dose combination nasal spray |
Drug product |
Formulation development and manufacturing site(s) |
| Metered-dose nasal spray system |
Device + packaging |
Fill-finish line and packaging supplier(s) |
Because supplier mapping requires product-specific dossier sources (e.g., FDA labels and annual reports that name manufacturing site(s), or patent prosecution history naming facilities, or inspection lists tied to application numbers), and because those dossier-level sources are not present in the materials available to this session, no supplier list can be stated.
Key Takeaways
- RYALTRIS comprises olopatadine hydrochloride + fluticasone propionate in a fixed-dose nasal spray.
- This conversation context does not contain named supplier identities for the APIs, drug product manufacturing, or fill-finish/packaging.
- Any “supplier list” beyond the above would require sourcing that is not available here.
FAQs
1. What APIs are in RYALTRIS?
RYALTRIS contains olopatadine hydrochloride and fluticasone propionate.
2. Is there an authoritative public supplier list in this context?
No. This context provides no named suppliers for API, formulation, fill-finish, or packaging.
3. What supplier categories should be identified for RYALTRIS?
The categories are API suppliers, drug product manufacturing/formulation supplier(s), and fill-finish/packaging supplier(s).
4. Does RYALTRIS require a specialized nasal spray fill-finish line?
Yes. A metered nasal spray requires dedicated fill-finish and device-compatible packaging processes.
5. Can upstream supplier mapping be done from only general product knowledge?
No. Accurate mapping requires dossier-level or regulator-linked manufacturing disclosures tied to the specific product and application.
References
[1] FDA Labeling for RYALTRIS (olopatadine hydrochloride and fluticasone propionate nasal spray), access not provided in this session.
